Showing 1941-1950 of 9245 results for "".
- ARTAS System Receives Canadian Medical Device License to Treat Hair Losshttps://practicaldermatology.com/news/20120229-artas_system_receives_canadian_medical_device_license_to_treat_hair_loss/2459861/Restoration Robotics, Inc., a privately-held medical device company, today announced that its revolutionary ARTAS™ System has received a Canadian Medical Device License and can now be marketed and sold within Canada. The physician controlled ARTAS™ System allows them to quickly identify and harvest
- The Medical Entrepreneur Symposium Announces Sponsorshttps://practicaldermatology.com/news/20120229-the_medical_entrepreneur_symposium_announces_sponsors/2459863/The Medical Entrepreneur Symposium has finalized agreements with several initial sponsors for its upcoming educational seminar. Citrix GotoMeeting, AdvancedMD, Bernstein Wealth Management, Allergan Cosmetic, Obagi, Merz Aesthetics, and BTL Exilis have all agreed to sponsor the two-and-a-half-day sym
- ARTAS Medical System Coming to Texashttps://practicaldermatology.com/news/20120224-artas_medical_system_coming_to_texas/2459864/The ARTAS System, the first and only FDA cleared, physician controlled, computer assisted technology that allows harvesting individual follicular units directly from the scalp, is coming to Texas. <a href="www.markbisharamd.com" target="_blank">Mark A. Bishara, MD, PA,</a> a cosmetic sur
- National Academy of Dermatology Nurse Practitioners Inaugural Conference in Mayhttps://practicaldermatology.com/news/20120224-national_academy_of_dermatology_nurse_practitioners__inaugural_conference_in_may/2459865/The inaugural conference of the National Academy of Dermatology Nurse Practitioners will be held May 2-5, 2012 in Clearwater Beach, FL at the Sheraton Sand Key Resort. Designed for all nurse practitioners regardless of experience or practice seting, the program covers both medical and aesthetic derm
- Global Derm Market Reaches $11.6 Billionhttps://practicaldermatology.com/news/20120224-global_derm_market_reaches_116_billion/2459867/The global prescription dermatologic therapy market grew 6.2% from 2009 to 2001, to reach $11.6 billion. A new MarketWatch.com. report notes that the most dramatic gains were in the antiaging/photodamage, hair loss and hair removal, psoriasi
- Health Canada Approves BMS' Yervoy for Melanomahttps://practicaldermatology.com/news/20120208-health_canada_approves_bms_yervoy_for_melanoma/2459869/Health Canada approved Yervoy (ipilimumab 3mg/kg, Bristol-Myers Squibb) for the treatment of unresectable or metastatic melanoma in patients who have failed or do not tolerate other systemic therapy for advanced diseas
- Global Study Maps Wide Disparities in Access to Dermatologic Carehttps://practicaldermatology.com/news/global-study-maps-wide-disparities-in-access-to-dermatologic-care/2488213/A global analysis of dermatologic care found substantial disparities in dermatologist availability, training opportunities, and access to specialty services, with lower-resource countries facing the greatest gaps. The cross-sectional study surveyed dermatology leaders across World Health O
- AI Beauty Tools May Favor Narrower Facial Aesthetic Standards: Supplementhttps://practicaldermatology.com/news/ai-beauty-tools-may-favor-narrower-facial-aesthetic-standards-supplement/2488121/Artificial intelligence (AI) is emerging as another influence on facial aesthetic standards, potentially affecting how patients perceive attractiveness and approach cosmetic procedures, according to brief review in The Journal of Craniofacial Surgery. The authors explored how AI s
- Upadacitinib Meets Primary Endpoint in Two Phase 3 Alopecia Areata Trialshttps://practicaldermatology.com/news/upadacitinib-meets-primary-endpoint-in-two-phase-3-alopecia-areata-trials/2488081/New data suggests upadacitinib was associated with significantly greater scalp hair regrowth than placebo among adults and adolescents with severe alopecia areata (AA), according to findings published online August 12 in JAMA Dermatology. The replicate UP-AA1 and UP-AA2 trials enr
- Study: One-Third of Pemphigus Cases Deviate From Classic Desmoglein Compensation Modelhttps://practicaldermatology.com/news/study-one-third-of-pemphigus-cases-deviate-from-classic-desmoglein-compensation-model/2487700/